Selected research
Industry Growth & Trends
Global Pegfilgrastim Injection Industry Growth and Trends Forecast to 2032
Market perspective
The global Pegfilgrastim Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Pegfilgrastim Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Pegfilgrastim Injection is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Pegfilgrastim Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Pegfilgrastim Injection include CSPC, Sandoz (Novartis), Qilu Pharmaceutical, Mylan, Pfizer, Jiangsu Hengrui Medicine, Fresenius Kabi, Amgen Inc. and Coherus BioSciences, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Pegfilgrastim Injection market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Pegfilgrastim Injection market size, estimates, and forecasts are presented in terms of sales volume (units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Pegfilgrastim Injection market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Pegfilgrastim Injection.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Pegfilgrastim Injection market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Pegfilgrastim Injection Market by Company
CSPC
Sandoz (Novartis)
Qilu Pharmaceutical
Mylan
Pfizer
Jiangsu Hengrui Medicine
Fresenius Kabi
Amgen Inc.
Coherus BioSciences, Inc.
Biocon Biologics Inc.
Pegfilgrastim Injection Segment by Type
Innovative Drugs
Generic Drugs
Pegfilgrastim Injection Segment by Application
Neoplastic Diseases
Blood Disorders
Others
Pegfilgrastim Injection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pegfilgrastim Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pegfilgrastim Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pegfilgrastim Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pegfilgrastim Injection manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Pegfilgrastim Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Innovative Drugs
- Generic Drugs
Applications
- Neoplastic Diseases
- Blood Disorders
- Others
Companies covered
- CSPC
- Sandoz (Novartis)
- Qilu Pharmaceutical
- Mylan
- Pfizer
- Jiangsu Hengrui Medicine
- Fresenius Kabi
- Amgen Inc.
- Coherus BioSciences, Inc.
- Biocon Biologics Inc.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Pegfilgrastim Injection Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Pegfilgrastim Injection Sales Estimates and Forecasts (2021-2032)
- 1.3 Pegfilgrastim Injection Market by Type
- 1.3.1 Innovative Drugs
- 1.3.2 Generic Drugs
- 1.4 Global Pegfilgrastim Injection Market Size by Type
- 1.4.1 Global Pegfilgrastim Injection Market Size Overview by Type (2021-2032)
- 1.4.2 Global Pegfilgrastim Injection Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Pegfilgrastim Injection Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Pegfilgrastim Injection Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Pegfilgrastim Injection Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Pegfilgrastim Injection Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Pegfilgrastim Injection Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Pegfilgrastim Injection Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Pegfilgrastim Injection Industry Trends
- 2.2 Pegfilgrastim Injection Industry Drivers
- 2.3 Pegfilgrastim Injection Industry Opportunities and Challenges
- 2.4 Pegfilgrastim Injection Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Pegfilgrastim Injection Revenue (2021-2026)
- 3.2 Global Top Players by Pegfilgrastim Injection Sales (2021-2026)
- 3.3 Global Top Players by Pegfilgrastim Injection Price (2021-2026)
- 3.4 Global Pegfilgrastim Injection Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Pegfilgrastim Injection Major Company Production Sites & Headquarters
- 3.6 Global Pegfilgrastim Injection Company, Product Type & Application
- 3.7 Global Pegfilgrastim Injection Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Pegfilgrastim Injection Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Pegfilgrastim Injection Players Market Share by Revenue in 2025
- 3.8.3 2025 Pegfilgrastim Injection Tier 1, Tier 2, and Tier 3
4 Pegfilgrastim Injection Regional Status and Outlook
- 4.1 Global Pegfilgrastim Injection Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Pegfilgrastim Injection Historic Market Size by Region
- 4.2.1 Global Pegfilgrastim Injection Sales in Volume by Region (2021-2026)
- 4.2.2 Global Pegfilgrastim Injection Sales in Value by Region (2021-2026)
- 4.2.3 Global Pegfilgrastim Injection Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Pegfilgrastim Injection Forecasted Market Size by Region
- 4.3.1 Global Pegfilgrastim Injection Sales in Volume by Region (2027-2032)
- 4.3.2 Global Pegfilgrastim Injection Sales in Value by Region (2027-2032)
- 4.3.3 Global Pegfilgrastim Injection Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Pegfilgrastim Injection by Application
- 5.1 Pegfilgrastim Injection Market by Application
- 5.1.1 Neoplastic Diseases
- 5.1.2 Blood Disorders
- 5.1.3 Others
- 5.2 Global Pegfilgrastim Injection Market Size by Application
- 5.2.1 Global Pegfilgrastim Injection Market Size Overview by Application (2021-2032)
- 5.2.2 Global Pegfilgrastim Injection Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Pegfilgrastim Injection Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Pegfilgrastim Injection Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Pegfilgrastim Injection Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Pegfilgrastim Injection Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Pegfilgrastim Injection Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Pegfilgrastim Injection Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 CSPC
- 6.1.1 CSPC Company Information
- 6.1.2 CSPC Business Overview
- 6.1.3 CSPC Pegfilgrastim Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 CSPC Pegfilgrastim Injection Product Portfolio
- 6.1.5 CSPC Recent Developments
- 6.2 Sandoz (Novartis)
- 6.2.1 Sandoz (Novartis) Company Information
- 6.2.2 Sandoz (Novartis) Business Overview
- 6.2.3 Sandoz (Novartis) Pegfilgrastim Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Sandoz (Novartis) Pegfilgrastim Injection Product Portfolio
- 6.2.5 Sandoz (Novartis) Recent Developments
- 6.3 Qilu Pharmaceutical
- 6.3.1 Qilu Pharmaceutical Company Information
- 6.3.2 Qilu Pharmaceutical Business Overview
- 6.3.3 Qilu Pharmaceutical Pegfilgrastim Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 Qilu Pharmaceutical Pegfilgrastim Injection Product Portfolio
- 6.3.5 Qilu Pharmaceutical Recent Developments
- 6.4 Mylan
- 6.4.1 Mylan Company Information
- 6.4.2 Mylan Business Overview
- 6.4.3 Mylan Pegfilgrastim Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 Mylan Pegfilgrastim Injection Product Portfolio
- 6.4.5 Mylan Recent Developments
- 6.5 Pfizer
- 6.5.1 Pfizer Company Information
- 6.5.2 Pfizer Business Overview
- 6.5.3 Pfizer Pegfilgrastim Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 Pfizer Pegfilgrastim Injection Product Portfolio
- 6.5.5 Pfizer Recent Developments
- 6.6 Jiangsu Hengrui Medicine
- 6.6.1 Jiangsu Hengrui Medicine Company Information
- 6.6.2 Jiangsu Hengrui Medicine Business Overview
- 6.6.3 Jiangsu Hengrui Medicine Pegfilgrastim Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 Jiangsu Hengrui Medicine Pegfilgrastim Injection Product Portfolio
- 6.6.5 Jiangsu Hengrui Medicine Recent Developments
- 6.7 Fresenius Kabi
- 6.7.1 Fresenius Kabi Company Information
- 6.7.2 Fresenius Kabi Business Overview
- 6.7.3 Fresenius Kabi Pegfilgrastim Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 Fresenius Kabi Pegfilgrastim Injection Product Portfolio
- 6.7.5 Fresenius Kabi Recent Developments
- 6.8 Amgen Inc.
- 6.8.1 Amgen Inc. Company Information
- 6.8.2 Amgen Inc. Business Overview
- 6.8.3 Amgen Inc. Pegfilgrastim Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.8.4 Amgen Inc. Pegfilgrastim Injection Product Portfolio
- 6.8.5 Amgen Inc. Recent Developments
- 6.9 Coherus BioSciences, Inc.
- 6.9.1 Coherus BioSciences, Inc. Company Information
- 6.9.2 Coherus BioSciences, Inc. Business Overview
- 6.9.3 Coherus BioSciences, Inc. Pegfilgrastim Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.9.4 Coherus BioSciences, Inc. Pegfilgrastim Injection Product Portfolio
- 6.9.5 Coherus BioSciences, Inc. Recent Developments
- 6.10 Biocon Biologics Inc.
- 6.10.1 Biocon Biologics Inc. Company Information
- 6.10.2 Biocon Biologics Inc. Business Overview
- 6.10.3 Biocon Biologics Inc. Pegfilgrastim Injection Sales, Revenue and Gross Margin (2021-2026)
- 6.10.4 Biocon Biologics Inc. Pegfilgrastim Injection Product Portfolio
- 6.10.5 Biocon Biologics Inc. Recent Developments
7 North America by Country
- 7.1 North America Pegfilgrastim Injection Sales by Country
- 7.1.1 North America Pegfilgrastim Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Pegfilgrastim Injection Sales by Country (2021-2026)
- 7.1.3 North America Pegfilgrastim Injection Sales Forecast by Country (2027-2032)
- 7.2 North America Pegfilgrastim Injection Market Size by Country
- 7.2.1 North America Pegfilgrastim Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Pegfilgrastim Injection Market Size by Country (2021-2026)
- 7.2.3 North America Pegfilgrastim Injection Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Pegfilgrastim Injection Sales by Country
- 8.1.1 Europe Pegfilgrastim Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Pegfilgrastim Injection Sales by Country (2021-2026)
- 8.1.3 Europe Pegfilgrastim Injection Sales Forecast by Country (2027-2032)
- 8.2 Europe Pegfilgrastim Injection Market Size by Country
- 8.2.1 Europe Pegfilgrastim Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Pegfilgrastim Injection Market Size by Country (2021-2026)
- 8.2.3 Europe Pegfilgrastim Injection Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Pegfilgrastim Injection Sales by Country
- 9.1.1 Asia-Pacific Pegfilgrastim Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Pegfilgrastim Injection Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Pegfilgrastim Injection Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Pegfilgrastim Injection Market Size by Country
- 9.2.1 Asia-Pacific Pegfilgrastim Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Pegfilgrastim Injection Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Pegfilgrastim Injection Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Pegfilgrastim Injection Sales by Country
- 10.1.1 South America Pegfilgrastim Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Pegfilgrastim Injection Sales by Country (2021-2026)
- 10.1.3 South America Pegfilgrastim Injection Sales Forecast by Country (2027-2032)
- 10.2 South America Pegfilgrastim Injection Market Size by Country
- 10.2.1 South America Pegfilgrastim Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Pegfilgrastim Injection Market Size by Country (2021-2026)
- 10.2.3 South America Pegfilgrastim Injection Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Pegfilgrastim Injection Sales by Country
- 11.1.1 Middle East and Africa Pegfilgrastim Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Pegfilgrastim Injection Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Pegfilgrastim Injection Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Pegfilgrastim Injection Market Size by Country
- 11.2.1 Middle East and Africa Pegfilgrastim Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Pegfilgrastim Injection Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Pegfilgrastim Injection Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Pegfilgrastim Injection Value Chain Analysis
- 12.1.1 Pegfilgrastim Injection Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Pegfilgrastim Injection Production Mode & Process
- 12.2 Pegfilgrastim Injection Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Pegfilgrastim Injection Distributors
- 12.2.3 Pegfilgrastim Injection Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst